<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511340</url>
  </required_header>
  <id_info>
    <org_study_id>HHGV678-204</org_study_id>
    <nct_id>NCT02511340</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients</brief_title>
  <official_title>Multi-center, Single Stage Phase II Study to Evaluate the Efficacy and Safety of Flumatinib in Accelerated or Blastic Phase Chronic Myelogenous Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib
      in accelerated or blastic Phase chronic myelogenous leukemia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, single-arm, open-label,phase II study to investigate efficacy and safety of
      Flumatinib in Chinese patients with accelerated or blastic Phase chronic myelogenous
      leukemia. The starting daily oral dose of Flumatinib is 600mg，core test is six cycles (each
      cycle is 28 days), collecting the core test data for primary efficacy analysis. The longest
      treatment time is 12 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed overall hematologic response（OHR）at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Flumatinib mesylate tablet 600 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flumatinib, 600mg, qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumatinib mesylate tablet 600 mg qd</intervention_name>
    <description>Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients</description>
    <arm_group_label>Flumatinib mesylate tablet 600 mg qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients age 18-75 year-old;

          -  ECOG 0 - 2;

          -  Newly diagnosed or previously treated Ph+ CML patients in accelerated or blastic
             Phase;

          -  Adequate organ function;

          -  Written informed consent prior to any study procedures being performed.

        Exclusion Criteria:

          -  Patients in Chronic and Blastic Phases;

          -  Previously treated with Flumatinib;

          -  Previously documented T315I mutations;

          -  Previous therapy within protocol defined timeframe, including:

               -  hydroxyurea within 24 hr,

               -  Imatinib or Nilotinib or Dasatinib within 28 days)

          -  Cardiac dysfunction ;

          -  History of congenital or acquired bleeding disorders unrelated to CML;

          -  Central nervous system leukemia;

          -  Previous malignancy except CML;

          -  Acute or chronic liver or severe kidney disease unrelated to CML;

          -  Pregnant, breastfeeding, child bearing potential but failed to take effective
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaiyan Liu</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

